Selling an ABA Company: What Actually Drives Value
Revenue matters less than most owners expect. Owner dependence, payer concentration, documentation quality and clean financials matter more.
Most owners who start thinking about selling assume the question is "what's my multiple?" The more useful question is "what would a buyer or partner actually be underwriting?" — because that's what determines both the number and whether a deal closes at all.
This is also worth reading if you have no intention of selling. Everything that increases value also makes the company easier to own.
What buyers and partners look at
Owner dependence. If the company can't operate without you, a buyer is purchasing a job they'll need to fill. This is the largest single value factor and the one owners most consistently underestimate.
Payer concentration and mix. Heavy concentration in one payer is a risk to whoever holds the company next — particularly where rates or policy are actively changing.
Documentation and compliance quality. Diligence will sample records. Weak documentation implies recoupment exposure, and exposure gets priced — or turns into an indemnity you carry after closing.
Staff retention and clinical leadership. A company whose clinicians are likely to leave is a company whose revenue is likely to leave.
Financial hygiene. Clean, consistent, reconciled books with revenue recognised sensibly. Messy financials don't just lower the number; they lengthen diligence, and long diligence kills deals.
Growth trajectory and headroom. Demonstrated growth, plus a credible reason there's more available.
The options between "keep it exactly as-is" and "sell it"
Owners frequently think this is binary. In practice the realistic range usually includes:
- Stay independent and hand off the operating load — keep ownership, stop being the operator.
- Bring in a partner for part of the company, taking some liquidity while staying involved.
- Join a shared-infrastructure network — keep ownership and brand, share the overhead.
- Sell a majority and stay on with a defined role and often a second bite later.
- Sell outright and exit on a defined timeline.
Each produces a very different outcome for you, your team and your families. Deciding which you actually want before talking to anyone is the highest-leverage thing you can do.
The timing problem
Owners who explore options while the company is stable consistently end up with better terms and more choices than owners who explore under pressure. A buyer can tell the difference immediately between a seller with alternatives and a seller who needs a transaction.
This is the practical case for stabilizing first: not because a sale is wrong, but because every option improves from a position of strength.
Twelve months of preparation, ranked
- Reduce owner dependence — name the decisions only you make and build a person or rule for each.
- Clean up documentation and fix any compliance exposure you already know about.
- Get financials reconciled, consistent and explainable month over month.
- Improve retention among clinical leadership specifically.
- Reduce payer concentration if it's extreme, or be ready to explain it credibly.
- Fix collections and AR — cash quality reads directly as business quality.
Every item on that list improves the company whether or not you ever transact. That's what makes it the right list.
A note on who you talk to
There is a real difference between someone helping you understand your options and someone sourcing a deal. Both exist in this market. The question worth asking early and directly is: whose interest are you representing, and how are you paid?
A useful conversation about strategic options should cost you nothing and commit you to nothing.
Where does your company actually stand?
The ABA Business Assessment turns all of this into a read on your specific situation — in about four minutes, with results on screen.